Overview

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Status:
Not yet recruiting

Trial end date:
2029-07-01

Target enrollment:

Participant gender:

Summary

This is a single-arm phase II study that will enroll a minimum of 41 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue imatinib. All patients must be restarted on imatinib at the time of relapse in order to be eligible for this trial.

Phase:

Phase 2

Details

Lead Sponsor:

Medical College of Wisconsin

Collaborator:

H. Jean Khoury Cure CML Consortium

Treatments:

Imatinib Mesylate